Non-nucleoside reverse transcriptase inhibitors: a review on pharmacokinetics, pharmacodynamics, safety and tolerability

Efficacy and Safety of Lersivirine (UK-453,061) Versus Efavirenz in Antiretroviral Treatment–Naive HIV-1–Infected Patients

(2013) Pietro Vernazza et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Resistance at Virological Failure Using Boosted Protease Inhibitors Versus Nonnucleoside Reverse Transcriptase Inhibitors As First-Line Antiretroviral Therapy—Implications for Sustained Efficacy of ART in Resource-Limited Settings

(2013) Andrew Hill et al.   JOURNAL OF INFECTIOUS DISEASES

Safety and Efficacy of GSK2248761, a Next-Generation Nonnucleoside Reverse Transcriptase Inhibitor, in Treatment-Naive HIV-1-Infected Subjects

(2012) Carlos Zala et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Antiviral Activity andIn VitroMutation Development Pathways of MK-6186, a Novel Nonnucleoside Reverse Transcriptase Inhibitor

(2012) Meiqing Lu et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Drug interaction profile for GSK2248761, a next generation non-nucleoside reverse transcriptase inhibitor

(2012) Steve Piscitelli et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

HIV-1 Antiretroviral Resistance

(2012) Michele W. Tang et al.   DRUGS

Effect of gender and race on the week 48 findings in treatment-naïve, HIV-1-infected patients enrolled in the randomized, phase III trials ECHO and THRIVE

(2012) S Hodder et al.   HIV MEDICINE

Efficacy and Safety of Rilpivirine (TMC278) Versus Efavirenz at 48 Weeks in Treatment-Naive HIV-1–Infected Patients

(2012) Calvin J. Cohen et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Rilpivirine: a new non-nucleoside reverse transcriptase inhibitor

(2012) M. Sharma et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Efficacy and Safety Outcomes Among Treatment-Experienced Women and Men Treated with Etravirine in Gender, Race and Clinical Experience

(2011) Sally Hodder et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES

Características de los fármacos antirretrovirales

(2011) Esteban Ribera et al.   ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA

Intracellular and plasma pharmacokinetics of 400 mg of etravirine once daily versus 200 mg of etravirine twice daily in HIV-infected patients

(2011) A. Gutierrez-Valencia et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Lack of a Clinically Relevant Effect of an Antacid on the Pharmacokinetics of Lersivirine

(2010) M. Vourvahis et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Phase 2a Randomized Controlled Trial of Short-Term Activity, Safety, and Pharmacokinetics of a Novel Nonnucleoside Reverse Transcriptase Inhibitor, RDEA806, in HIV-1-Positive, Antiretroviral-Naive Subjects

(2010) G. Moyle et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Concomitant Administration of BILR 355/r with Emtricitabine/Tenofovir Disoproxil Fumarate Increases Exposure to Emtricitabine and Tenofovir: A Randomized, Open-Label, Prospective Study

(2010) Fenglei Huang et al.   BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY

Excretion and Metabolism of Lersivirine (5- benzene-1,3-dicarbonitrile), a Next-Generation Non-Nucleoside Reverse Transcriptase Inhibitor, after Administration of [14C]Lersivirine to Healthy Volunteers

(2010) M. Vourvahis et al.   DRUG METABOLISM AND DISPOSITION

LC–MS/MS determination of etravirine in rat plasma and its application in pharmacokinetic studies

(2010) Cyril V. Abobo et al.   JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES

Coadministration With Lopinavir and Ritonavir Decreases Exposure to BILR 355, a Nonnucleoside Reverse Transcriptase Inhibitor, in Healthy Volunteers

(2010) Fenglei Huang et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Evaluation of steady-state pharmacokinetic interactions between ritonavir-boosted BILR 355, a non-nucleoside reverse transcriptase inhibitor, and lamivudine/zidovudine in healthy subjects

(2010) F. Huang et al.   JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS

Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment

(2009) Richard H Haubrich et al.   AIDS

Activity, pharmacokinetics and safety of lersivirine (UK-453,061), a next-generation nonnucleoside reverse transcriptase inhibitor, during 7-day monotherapy in HIV-1-infected patients

(2009) Gerd Fätkenheuer et al.   AIDS

Lack of increased hepatotoxicity in HIV-infected pregnant women receiving nevirapine compared with other antiretrovirals

(2009) David W Ouyang et al.   AIDS

Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: week 96 results of a phase IIb randomized trial

(2009) Anton L Pozniak et al.   AIDS

TMC278, a Next-Generation Nonnucleoside Reverse Transcriptase Inhibitor (NNRTI), Active against Wild-Type and NNRTI-Resistant HIV-1

(2009) H. Azijn et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Human Immunodeficiency Virus Type 1 Recombinant Reverse Transcriptase Enzymes Containing the G190A and Y181C Resistance Mutations Remain Sensitive to Etravirine

(2009) H. Xu et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Antiviral Activity of MK-4965, a Novel Nonnucleoside Reverse Transcriptase Inhibitor

(2009) M.-T. Lai et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: A review of the last 20 years (1989–2009)

(2009) Marie-Pierre de Béthune   ANTIVIRAL RESEARCH

Pharmacokinetics and drug–drug interactions of antiretrovirals: An update

(2009) Laura Dickinson et al.   ANTIVIRAL RESEARCH

Etravirine, a Next‐Generation Nonnucleoside Reverse‐Transcriptase Inhbitor

(2009) Leonard B. Johnson et al.   CLINICAL INFECTIOUS DISEASES

Clinical Pharmacokinetics and Pharmacodynamics of Etravirine

(2009) Monika Schöller-Gyüre et al.   CLINICAL PHARMACOKINETICS

Etravirine: A second-generation nonnucleoside reverse transcriptase inhibitor (NNRTI) active against NNRTI-resistant strains of HIV

(2009) Daryl S. Schiller et al.   CLINICAL THERAPEUTICS

Efavirenz in the therapy of HIV infection

(2009) Natella Y Rakhmanina et al.   Expert Opinion on Drug Metabolism & Toxicology

Biaryl Ethers as Novel Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Key Mutant Viruses

(2009) Dai-Shi Su et al.   JOURNAL OF MEDICINAL CHEMISTRY

Pharmacokinetics of BILR 355 after Multiple Oral Doses Coadministered with a Low Dose of Ritonavir

(2008) F. Huang et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Towards novel S-DABOC inhibitors: Synthesis, biological investigation, and molecular modeling studies

(2008) Marco Radi et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Antiretroviral Drug Resistance Testing in Adult HIV‐1 Infection: 2008 Recommendations of an International AIDS Society–USA Panel

(2008) Martin S. Hirsch et al.   CLINICAL INFECTIOUS DISEASES

Efavirenz – Still First-line King?

(2008) Brookie M Best et al.   Expert Opinion on Drug Metabolism & Toxicology

Adverse cutaneous reactions associated with the newest antiretroviral drugs in patients with human immunodeficiency virus infection

(2008) J. Borras-Blasco et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Design of Annulated Pyrazoles as Inhibitors of HIV-1 Reverse Transcriptase∥

(2008) Zachary K. Sweeney et al.   JOURNAL OF MEDICINAL CHEMISTRY

Effects of Different Meal Compositions and Fasted State on the Oral Bioavailability of Etravirine

(2008) Monika Schöller-Gyüre et al.   PHARMACOTHERAPY